The future of cancer drug research just might be in Omaha, Nebraska, between a Panda Express and a Mattress Firm.
Here, in an otherwise unremarkable storefront, a little-known clinic called XCancer has become one of the most trusted research partners of pharmaceutical companies seeking to test experimental prostate cancer medicines. XCancer and its sole physician, Luke Nordquist, have participated in more than 200 trials over 15 years, and played a leading role in testing Novartis AG’s widely advertised blockbuster, Pluvicto.
A big draw is speed: Nordquist says he can open a trial in as little as two weeks, unlike ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.